In this article
Early diagnosis of pancreatic cancer is difficult and it lacks specific drugs. Pancreatic cancer is one of the deadliest tumors, and at present, treatment is generally carried out through general chemotherapy regimens. Nupr1 protein is an "intrinsically disordered protein" that, as early as the 1990s, scientists identified as being involved in the development of pancreatic cancer.
Researchers from France and Spain have discovered that a substance previously used to treat anxiety can interfere with the development of pancreatic cancer. Scientists have now discovered molecules that can inhibit the activity of the Nupr1 protein. This study screened molecules that effectively inhibit Nupr1 activity from more than 1,000 drugs that have already been approved for the treatment of various diseases. Through a combination of computer simulation and pharmacological testing, it was confirmed that the molecule can interact with the Nupr1 protein. In vitro experiments show that it can reduce the viability and metastasis ability of tumor cells, and completely inhibit the possibility of colony formation. The effective compound was also tested in animals, proving that it can prevent the development of the disease. This compound is trifluoperazine.
Trifluoperazine was previously used only as an antipsychotic drug in clinical settings, and it is now shown that its antitumor efficacy is very promising. This study has changed the direction of pancreatic cancer treatment, and inhibiting Nupr1 may become a new therapeutic direction for the treatment of this cancer.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.